News

MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MW005 shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel,…

9 months ago

TerrAscend Reaches Four Dispensary Cap in Maryland with Closing of Herbiculture Acquisition

Acquisition expected to be immediately accretive on an EBITDA and cashflow basisTORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend”…

9 months ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

CANTON, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…

9 months ago

Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer

Human Resources Leader with Nearly 30 Years of Experience and Commitment to Professional Services EnvironmentMORRISVILLE, N.C., July 10, 2023 (GLOBE NEWSWIRE)…

9 months ago

Evelo Biosciences Announces $25.5 Million Private Placement

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel…

9 months ago

Societal CDMO Selected by Spinnaker Biosciences to Provide CDMO Services to Support Clinical Development of Novel Therapeutic Candidate

Activities will be Conducted at Societal CDMO’s San Diego Facility and Span Analytic Method Transfer, Process Development, and CGMP ManufacturingSAN…

9 months ago

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer

Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC)…

9 months ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation…

9 months ago

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity

Preliminary Data Suggest that Oxytocin May Simultaneously Reduce Energy Intake and Increase Energy Expenditure TNX-1900 (Intranasal Potentiated Oxytocin) May Serve…

9 months ago